S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Ergomed Share Forecast, Price & News

GBX 1,275
-25.00 (-1.92%)
(As of 01/14/2022 09:00 PM ET)
Today's Range
50-Day Range
52-Week Range
13,533 shs
Average Volume
57,685 shs
Market Capitalization
£626.43 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ERGO News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

Ergomed logo

About Ergomed

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
£102.05 million
Cash Flow
GBX 48.31 per share
Book Value
GBX 120.40 per share


Pretax Margin




Free Float
Market Cap
£626.43 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)


Overall MarketRank

1.50 out of 5 stars

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Ergomed (LON:ERGO) Frequently Asked Questions

Is Ergomed a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ergomed stock.
View analyst ratings for Ergomed
or view top-rated stocks.

How has Ergomed's stock been impacted by Coronavirus (COVID-19)?

Ergomed's stock was trading at GBX 392 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ERGO shares have increased by 225.3% and is now trading at GBX 1,275.
View which stocks have been most impacted by COVID-19

When is Ergomed's next earnings date?

Ergomed is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Ergomed

How were Ergomed's earnings last quarter?

Ergomed plc (LON:ERGO) announced its quarterly earnings results on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The company had revenue of $22.91 million for the quarter.
View Ergomed's earnings history

What price target have analysts set for ERGO?

1 brokerages have issued 12-month target prices for Ergomed's stock. Their forecasts range from GBX 1,550 to GBX 1,550. On average, they anticipate Ergomed's stock price to reach GBX 1,550 in the next twelve months. This suggests a possible upside of 21.6% from the stock's current price.
View analysts' price targets for Ergomed
or view top-rated stocks among Wall Street analysts.

Who are Ergomed's key executives?

Ergomed's management team includes the following people:
  • Dr. Miroslav Reljanovic, Founder & Exec. Chairman (Age 62, Pay $214.16k)
  • Mr. Richard T. Barfield, CFO & Exec. Director (Age 63, Pay $264.82k)
  • Ms. Sanja Juric, Gen. Counsel & Company Sec.
  • Dr. Michael Forstner, Head of Risk Management & Pharmacoepidemiology
  • Ms. Roy Ovel, Chief Commercial Officer
  • Ms. Sally Amanuel, Pres of PrimeVigilance
  • Dr. Gordana Tonkovic, Pres of CRO

What other stocks do shareholders of Ergomed own?

What is Ergomed's stock symbol?

Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

How do I buy shares of Ergomed?

Shares of ERGO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Ergomed's stock price today?

One share of ERGO stock can currently be purchased for approximately GBX 1,275.

How much money does Ergomed make?

Ergomed has a market capitalization of £626.43 million and generates £102.05 million in revenue each year.

How many employees does Ergomed have?

Ergomed employs 7 workers across the globe.

What is Ergomed's official website?

The official website for Ergomed is www.ergomedplc.com.

Where are Ergomed's headquarters?

How can I contact Ergomed?

Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-503205.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.